106 results
ARS
2023 FY
CRBU
Caribou Biosciences Inc
25 Apr 24
Annual report to shareholders
4:06pm
parties. If we fail to comply with our obligations under these agreements, we could lose intellectual property rights and be subject to litigation from our … . In addition, there is substantial patent infringement litigation in the biopharmaceutical industry and, in the future, we may bring or defend such litigation
8-K
EX-99.2
CRBU
Caribou Biosciences Inc
4 Apr 24
Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus
4:05pm
, are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements speak only
8-K
CRBU
Caribou Biosciences Inc
4 Apr 24
Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus
4:05pm
the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not historical facts are forward-looking statements. Forward
8-K
EX-99.1
CRBU
Caribou Biosciences Inc
4 Apr 24
Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus
4:05pm
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking
8-K
EX-99.1
yexz8i3o
11 Mar 24
Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
4:22pm
8-K
qqh67av6fxltcc
8 Jan 24
Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024
8:00am
8-K
EX-99.1
eeg0rnnhnnmptt0
8 Jan 24
Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024
8:00am
8-K
EX-99.1
35u1ssu8c
12 Dec 23
Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024
4:05pm
8-K
spfp3f
12 Dec 23
Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024
4:05pm
8-K
EX-99.1
zive8q2 hr7se2xb
7 Nov 23
Caribou Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update
4:02pm
8-K
EX-99.1
c8rngqmb5vx whox6x
18 Oct 23
Regulation FD Disclosure
8:02am
8-K
EX-99.1
aj5giy17f11j
8 Aug 23
Caribou Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update
4:03pm
8-K
EX-1.1
3u4oy q9e5syxo
14 Jul 23
Caribou Biosciences Announces Proposed Public Offering of Common Stock
6:33pm
8-K
EX-99.1
vl75pv t6
14 Jul 23
Caribou Biosciences Announces Proposed Public Offering of Common Stock
6:33pm
8-K
EX-99.2
0zi3tdwc66aath2zak
14 Jul 23
Caribou Biosciences Announces Proposed Public Offering of Common Stock
6:33pm